This trial is unknown!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Type2 Diabetes or Kidney Diseases
and you are
between 18 and 85
years old
The primary goal of this phase is to monitor the long-term effects.
The treatment is already on the market.
Show me locations

The purpose

This is a prospective study to evaluate effect of Exenatide extended release treatment for 1 year on albuminuria levels in T2DM patients with micro- and macroalbuminuria compared to placebo.

Provided treatments

  • Drug: Exenatide Extended Release for Inj Susp 2 MG
  • Drug: Placebos

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT03029351. The sponsor of the trial is University at Buffalo and it is looking for 90 volunteers for the current phase.
Official trial title:
GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes